Abstract
Prolactinomas are the most prevalent functional benign pituitary tumors due to a pituitary micro- or macroadenoma. The majority of patients presents with infertility and gonadal dysfunction. A dopamine agonist (DA) (bromocriptine or cabergoline) is the treatment of choice that can normalize prolactin levels, reduce tumor size, and restore ovulation and fertility. Cabergoline generally preferred over bromocriptine because of its higher efficacy and tolerability. Managing prolactinomas during pregnancy may be challenging. During pregnancy, the pituitary gland undergoes global hyperplasia due to a progressive increase in serum estrogens level that may lead to increase of the tumor volume with potential mass effect and visual loss. The risk of tumor enlargement may occur in 3% of those with microadenomas, 32% in those with macroadenomas that were not previously operated on, and 4.8% of those with macroadenomas with prior ablative treatment. Though both drugs appear to be safe during pregnancy, the data on fetal exposure to DAs during pregnancy have been reported with bromocriptine far exceeds that of cabergoline with no association of increased risk of pregnancy loss and premature delivery. It is advisable to stop the use of DAs immediately once pregnancy is confirmed, except in the case of women with invasive macroprolactinomas or pressure symptoms. This review outlines the therapeutic approach to prolactinoma during pregnancy, with emphasis on the safety of available DA therapy.
Introduction
Prolactinomas are adenomas arising from lactotroph cells in the pituitary gland that secrete prolactin, and are considered the most frequently diagnosed functioning pituitary tumor type, accounting for about 40% of all pituitary adenomas (1). Prolactin production and release is mediated via tonic inhibition by dopamine secreted by the hypothalamus. The breast is the main target tissue for prolactin, but prolactin receptors have been found in several tissues, including the liver, ovary, testis, and prostate (2). The primary action of prolactin is the initiation and maintenance of lactation, but it can act as a growth factor, neurotransmitter, or immunoregulator via autocrine or paracrine mechanisms (3).
Prolactinomas are one of the causes of hyperprolactinemia, a condition in which 90% are intersellar adenomas and 10% are macroadenomas (≥10 mm) (4). Prolactinomas occur with a prevalence of 60–100 cases per million (1). It is more common in women, particularly during the reproductive period. The highest incidence rate was found in women between 25 and 34 years of age: 23.9/100,000 person-years (4). In women, prolactinomas are usually microadenomas (<10 mm) presenting with high-prolactin levels, which leads to amenorrhea, galactorrhea, and infertility. Men with prolactinomas frequently present with symptoms of mass effects, such as headache and visual loss, and sometimes hypogonadism and infertility. Bone loss may occur as a long-term consequence of hyperprolactinemia in both men and women.
Dopamine agonists (DAs) have been increasingly used as a treatment of choice for prolactinomas as it normalizes prolactin levels and leads to tumor shrinkage. Surgery currently being reserved for resistance or intolerance to DA, while radiotherapy used only in cases of surgical failure or resistance to DA.
During pregnancy, the pituitary gland undergoes global hyperplasia due to a progressive increase in serum estrogens level that may lead to increase of the tumor volume with potential mass effect and visual loss, which poses significant challenge to endocrinologists.
Prolactinoma during Pregnancy
Tumor cells in patients with prolactinomas express estrogen receptors; as a result of the increased estrogen level during pregnancy (5), there can be a substantial increase in the volume of the prolactinoma, with a progressive increase in serum prolactin due to lactotroph cell hyperplasia (6). The main concern is possible tumor enlargement during pregnancy. The risk of tumor enlargement during pregnancy is found to depend on tumor size. Data in the literature indicate that although tumor enlargement is only 3% for microprolactinomas, it is as high as 32% for macroprolactinomas that were not previously operated on (7).
A magnetic resonance imaging (MRI) should be done before conception to document tumor size and to serve as a baseline for comparison with MRIs done during pregnancy. Furthermore, MRI is helpful in distinguishing between hemorrhage into a tumor versus simple tumor enlargement during pregnancy (8).
Although prolactinomas have been found to be amenable to medical treatment during pregnancy, especially with DAs such as bromocriptine, not enough safety data are available to recommend the routine use of these drugs during pregnancy. The endocrine society clinical practice guidelines for the management and treatment of prolactinomas recommend the discontinuation of DAs shortly after confirmation of pregnancy, with the exception of women with invasive macroprolactinomas (5).
Bromocriptine is an ergoline derivative, a dopamine D2 receptor agonist with agonist and antagonistic properties on D1 receptors. It is generally required to multiple dosing throughout the day because of its short half life (9–11). In women taking bromocriptine during early pregnancy, the incidence of abortions, ectopic pregnancies, or congenital malformations is no higher than that in the general population (12). In a study of 2,587 pregnant women, out of which 2,437 were to increase the risk of spontaneous abortion, congenital abnormalities, or multiple pregnancies, and did not affect post-natal development (13). In other studies, among 6,329 patients treated with bromocriptine during early pregnancy, the risk of spontaneous abortions was 9.9%, which was not higher than that in the general population (10.9%) (7, 14). Moreover, long-term follow-up to 9 years of children born from mothers taking bromocriptine did not cause detrimental effects on fetal outcomes in term of physical development as well as no psychomotor developmental abnormality reported to 5.5 years (1–20 years) follow-up (15).
Furthermore, optimal outcome was found with continuous use of bromocriptine throughout pregnancy in around 100 cases (16).
Cabergoline is an ergoline derivative DA with higher affinity and selectivity for D2 dopamine receptors. It has long duration of action allowing administration once or twice weekly with better tolerability and patient compliance (17–20). Moreover, pregnancy rate is higher with cabergoline in infertile women with prolactinoma than with bromocriptine (21).
The same results have been reported in women who were on cabergoline before and during pregnancy (22, 23). In one report, over 800 such pregnancies have been described (24) (of which approximately 350 were exposed during the first weeks of pregnancy), with no significant difference in the frequency of spontaneous abortion, premature delivery, multiple pregnancy, or neonatal malformations (25, 26).
In retrospective study on 103 pregnancies in 90 women with hyperprolactinemia and the follow-up of the 61 children, no significant abnormalities related neither to cabergoline doses nor to the time of exposure (27). Data of 12 years follow-up in the children born from mother treated with cabergoline showed no influence on their post-natal development such as physical problems or of psychomotor retardation (28). In consistent with previous studies, finding from meta-analysis showed no significant increase in the risk of miscarriages or fetal malformation with DA used (29).
Quinagolide is a non-ergot DA, with selective dopamine-2 receptor agonist and long-lasting prolactin lowering effect. It generally taken once daily and has better tolerability and convenient dosing schedule than bromocriptine (13, 30, 31). It has limited safety compared with bromocriptine. In a review of 176 pregnancies in which quinagolide was used (average of 37 days), spontaneous abortion occurred in 14%, 1 had premature delivery, and 1 had ectopic gestation (13). In another small study of nine pregnancies, there were two cases treated with two quinagolide and had no complications (31).
Over 200 pregnancies have been recorded in women taking quinagolide, and no apparent adverse effects on pregnancy or fetal development have been detected (32).
Hence, every woman with prolactinomas should be made aware of the natural history of prolactinomas and should discuss her plans to conceive with her physician, in order to be carefully evaluated prior to becoming pregnant.
The determination of the appropriate treatment option is an individual choice depending mainly on tumor size. The proposed therapeutic approach is shown in Figure 1 (33). The outcomes of prolactinomas after pregnancy have been extensively discussed, with variable results. A recent study showed a prolactin normalization rate of more than 40% without medical treatment, for a median follow-up of 22 months after delivery and cessation of lactation (34).
Figure 1
Managing Microprolactinomas during Pregnancy
Microprolactinomas in non-pregnant women tend to follow a benign course. The risk of significant asymptomatic tumor growth during pregnancy is 4.5% (35), and that of symptomatic tumor growth is <2% (36). The risk of the development of new neurological sequelae (headaches, optic nerve compression, etc.) ranges from 1.6 to 5.5% (37). Prolactin tends to increase during pregnancy; therefore, it does not reliably reflect an increase in tumor size and is not useful for clinical assessment.
In the context of the very low risk of microprolactinoma enlargement during pregnancy, there is considerable evidence supporting the discontinuation of DA treatment once pregnancy is confirmed. The patient should be told that the risk of enlargement of the adenoma during pregnancy is very small, and medical treatment will likely be effective if symptoms do occur.
The patient should be advised to report for urgent assessment in case of unusual symptoms such as severe headache or visual disturbance, to rule out the possibility of tumor enlargement. Serial prolactin determinations are not necessary due to the high variability of prolactin during pregnancy (38).
The patient should undergo baseline formal visual field testing at the time of diagnosis and should be followed clinically every 2–3 months during pregnancy (33), but serial MRI examinations or visual field testing during pregnancy is not required. However, there is no data documenting harm to the fetus from either MRI scans or gadolinium (8).
In case the patient becomes symptomatic with visual disturbance or progressive headaches, an MRI without gadolinium (not a CT) should be performed to assess changes in tumor size (39).
If substantial tumor growth is evident, the DA bromocriptine should be restarted immediately (36), because it is the first drug of choice in these cases.
For women who remain symptom-free throughout pregnancy, serum prolactin should be measured 2 months after delivery or cessation of nursing, and if it is similar to the pretreatment value, the drug should be restarted (40). Similarly, for women wishing to breastfeed, an MRI scan should be done to ensure the stability of the tumor within 4–6 weeks of delivery (37), as DAs will decrease serum PRL levels, subsequently impairing lactation.
Managing Macroprolactinomas during Pregnancy
In women, macroprolactinomas occur less frequently than microprolactinomas. In case of macroprolactinoma, symptomatic tumor enlargement occurs in 20–30% of cases (41). It has been reported that the risk of clinically significant tumor enlargement falls from over 30 to <5%, if the patient is treated with radiation or surgery before pregnancy (25).
Pregnant women with large tumors and those with extrasellar extension who have stopped bromocriptine are at risk for tumor growth, and formal visual field testing should be done in each trimester. Just like in microprolactinomas, it is not necessary to measure serum prolactin levels throughout pregnancy, because levels do not uniformly increase during gestation and do not correlate with tumor enlargement (8, 25). Furthermore, in these cases, the treatment should be individualized, as data comparing various management strategies are lacking.
The patient should be informed about the relatively higher risk of tumor enlargement, the need for normalization of prolactin, and the importance of treatment before conception.
In the case of intrasellar and small macroprolactinomas that do not abut the optic chiasm, DAs should be discontinued when pregnancy is confirmed.
The patient should be advised about the symptoms and the need for urgent evaluation once they appear. Close clinical monitoring should be undertaken with formal visual field testing during each trimester. If the patient reports headache or a change in vision, an MRI should be performed. If the MRI finding is consistent with tumor enlargement, the woman should be retreated with a DA (5).
Bromocriptine is considered as the first drug of choice, and it usually decreases the size of the adenoma and eliminates symptoms (42). Cabergoline may be considered if the adenoma does not respond to bromocriptine (43).
If the enlarged tumor does not respond to cabergoline therapy, alternatives include transsphenoidal surgery in the second trimester, or delivery if the pregnancy is advanced enough (16, 25, 41).
Patients with large macroprolactinomas and those with extrasellar extension are strongly discouraged from conceiving until definitive therapy is undertaken. Therapy with surgical debulking may be considered prior to pregnancy, because surgery or radiation has been shown to decrease the risks of symptomatic tumor enlargement (25), but there is high risk of hypopituitarism in these cases. However, debulking surgery is a less preferable option, since medical therapy during pregnancy is probably less harmful than surgery (41). Women with prolactinomas that are resistant to DAs are usually infertile. Therefore, pregnancy is unexpected in these cases, unless they undergo ovarian stimulation with gonadotropins or GnRH. Moreover, pregnancy is not recommended in women with drug resistant large macroprolactinomas and they should not conceive even if the tumor is intrasellar, until the size is reduced by transsphenoidal surgery.
Surgery is an option in cases with no tumor reduction during medical treatment with DA, or in those who developed tumor growth in a previous pregnancy (44).
Impact of Pregnancy and Breastfeeding on Prolactin Levels, Tumor Volume, and Remission Rate
The current literature demonstrates that pregnancy induces remission of hyperprolactinemia in two-thirds of women after discontinuation of DA. In one study, pregnancy has been found to induce remission in 76% of non-tumoral hyperprolactinemia (NTHP), 70% in microprolactinomas, and 64% in macroprolactinomas with higher recurrence rate among patients with macroprolactinomas and those with microprolactinomas with visible tumor on MRI at the time of treatment withdrawal (45).
In recent study, complete remission was found in 100% with NTHP, 66% of patients with microprolactinomas, and 70% with macroprolactinomas (46). Underlying mechanisms are uncertain but have generally been attributed to the autoinfarction of the tumor (46).
On the other hand, there is no data to suggest breastfeeding is associated with an increased prolactin production or risk of tumor enlargement (28, 46). Thus, women could breastfeed normally and restart DA after cessation of lactation.
Conclusion
Managing prolactinoma during pregnancy is challenging. Clinical trials highlighting the outcomes of medical therapy versus other therapies are scarce; therefore, the patient is treated on an individual basis. The outcome of microadenoma is excellent, allowing patients to safely discontinue DAs with close clinical monitoring; on the other hand, macroadenoma needs to be managed before conception, as the risk of tumor enlargement is relatively high.
Statements
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
CiccarelliADalyAFBeckersA. The epidemiology of prolactinomas. Pituitary (2005) 8(1):3–6.10.1007/s11102-005-5079-0
2
InderWJ. Hyperprolactinaemia – differential diagnosis, investigation and management. Eur Endocr Rev (2006):76–1002.
3
KarsMDekkersOMPereiraAMRomijnJA. Update in prolactinomas. Neth J Med (2010) 68(3):104–12.
4
MolitchME. Prolactinoma. Pituitary. Cambridge, IN: Blackwell Science (1995). p. 433–77.
5
MelmedSCasanuevaFFHoffmanARKleinbergDLMontoriVMSchlechteJAet alDiagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2011) 96(2):273–88.10.1210/jc.2010-1692
6
PichonMFBressionDPeillonFMilgromE. Estrogen receptors in human pituitary adenomas. J Clin Endocrinol Metab (1980) 51(4):897–902.10.1210/jcem-51-4-897
7
GillamMPMolitchMELombardiGColaoA. Advances in the treatment of prolactinomas. Endocr Rev (2006) 27(5):485–534.10.1210/er.2005-9998
8
MolitchME. Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma. Eur J Endocrinol (2015) 172(5):R205–13.10.1530/EJE-14-0848
9
MahPMWebsterJ. Hyperprolactinemia: etiology, diagnosis, and management. Semin Reprod Med (2002) 20(4):365–74.10.1055/s-2002-36709
10
BillerBM. Hyperprolactinemia. Int J Fertil Womens Med (1999) 44(2):74–7.
11
BankowskiBJZacurHA. Dopamine agonist therapy for hyperprolactinemia. Clin Obstet Gynecol (2003) 46(2):349–62.10.1097/00003081-200306000-00013
12
KruppPMonkaC. Bromocriptine in pregnancy: safety aspects. Klin Wochenschr (1987) 65(17):823–7.10.1007/BF01727477
13
WebsterJ. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Safety (1996) 14(4):228–38.10.2165/00002018-199614040-00003
14
Nybo AndersenAMWohlfahrtJChristensPOlsenJMelbyeM. Maternal age and fetal loss: population based register linkage study. BMJ (2000) 320(7251):1708–12.10.1136/bmj.320.7251.1708
15
Shibli-RahhalASchlechteJ. Hyperprolactinemia and infertility. Endocrinol Metab Clin North Am (2011) 40(4):837–46.10.1016/j.ecl.2011.08.008
16
ChrisoulidouABoudinaMKaravitakiNBiliEWassJ. Pituitary disorders in pregnancy. Hormones (2015) 14(1):70–80.10.14310/horm.2002.1575
17
ColaoADi SarnoASarnacchiaroFFeroneDDi RenzoGMerolaBet alProlactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab (1997) 82(3):876–83.10.1210/jcem.82.8.4178-3
18
VerhelstJAbsRMaiterDvan den BruelAVandewegheMVelkeniersBet alCabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab (1999) 84(7):2518–22.10.1210/jcem.84.7.5810
19
SerriOChikCLUrEEzzatS. Diagnosis and management of hyperprolactinemia. CMAJ (2003) 169(6):575–81.
20
LiuJKCouldwellWT. Contemporary management of prolactinomas. Neurosurg Focus (2004) 16(4):E2.10.3171/foc.2004.16.4.3
21
OnoMMikiNAmanoKKawamataTSekiTMakinoRet alIndividualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas. J Clin Endocrinol Metab (2010) 95(6):2672–9.10.1210/jc.2009-2605
22
CiccarelliEGrottoliSRazzorePGaiaDBertagnaACirilloSet alLong-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy. J Endocrinol Invest (1997) 20(9):547–51.10.1007/BF03348017
23
JonesJBashirTOlneyJWheatleyT. Cabergoline treatment for a large macroprolactinoma throughout pregnancy. J Obstet Gynaecol (1997) 17(4):375–6.10.1080/01443619750112916
24
MolitchME. Prolactinoma in pregnancy. Best Pract Res Clin Endocrinol Metab (2011) 25(6):885–96.10.1016/j.beem.2011.05.011
25
MusolinoNRBronsteinMD. Prolactinomas and Pregnancy. Kluwer Academic Publishers (2001). p. 91–108.
26
RicciEParazziniFMottaTFerrariCIColaoAClavennaAet alPregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol (2002) 16(6):791–3.10.1016/S0890-6238(02)00055-2
27
StalldeckerGMallea-GilMSGuitelmanMAlfieriABallarinoMCBoeroLet alEffects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature. Pituitary (2010) 13(4):345–50.10.1007/s11102-010-0243-6
28
LebbeMHubinontCBernardPMaiterD. Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women. Clin Endocrinol (2010) 73(2):236–42.10.1111/j.1365-2265.2010.03808.x
29
WangATMullanRJLaneMAHazemAPrasadCGathaiyaNWet alTreatment of hyperprolactinemia: a systematic review and meta-analysis. Syst Rev (2012) 1:33.10.1186/2046-4053-1-33
30
DuranteauLChansonPLavoinneAHorlaitSLubetzkiJKuhnJM. Effect of the new dopaminergic agonist CV 205-502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas. Clin Endocrinol (1991) 34(1):25–9.10.1111/j.1365-2265.1991.tb01731.x
31
MorangeIBarlierAPellegriniIBrueTEnjalbertAJaquetP. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy. Eur J Endocrinol (1996) 135(4):413–20.10.1530/eje.0.1350413
32
WebsterJ. Clinical management of prolactinomas. Baillieres Best Pract Res Clin Endocrinol Metab (1999) 13(3):395–408.10.1053/beem.1999.0030
33
ImranSAUrEClarkeDB. Managing prolactin-secreting adenomas during pregnancy. Can Fam Physician (2007) 53(4):653–8.
34
DomingueMEDevuystFAlexopoulouOCorvilainBMaiterD. Outcome of prolactinoma after pregnancy and lactation: a study on 73 patients. Clin Endocrinol (2014) 80(5):642–8.10.1111/cen.12370
35
MolitchME. Pregnancy and the hyperprolactinemic woman. N Engl J Med (1985) 312(21):1364–70.10.1056/NEJM198505233122106
36
KupersmithMJRosenbergCKleinbergD. Visual loss in pregnant women with pituitary adenomas. Ann Intern Med (1994) 121(7):473–7.10.7326/0003-4819-121-7-199410010-00001
37
GemzellCWangCF. Outcome of pregnancy in women with pituitary adenoma. Fertil Steril (1979) 31(4):363–72.
38
SchlechteJA. Clinical practice. Prolactinoma. N Engl J Med (2003) 349(21):2035–41.10.1056/NEJMcp025334
39
SchlechteJA. Long-term management of prolactinomas. J Clin Endocrinol Metab (2007) 92(8):2861–5.10.1210/jc.2007-0836
40
LawayBAMirSA. Pregnancy and pituitary disorders: challenges in diagnosis and management. Indian J Endocrinol Metab (2013) 17(6):996–1004.10.4103/2230-8210.122608
41
MolitchME. Management of prolactinomas during pregnancy. J Reprod Med (1999) 44(12 Suppl):1121–6.
42
van RoonEvan der VijverJCGerretsenGHeksterREWattendorffRA. Rapid regression of a suprasellar extending prolactinoma after bromocriptine treatment during pregnancy. Fertil Steril (1981) 36(2):173–7.
43
LiuCTyrrellJB. Successful treatment of a large macroprolactinoma with cabergoline during pregnancy. Pituitary (2001) 4(3):179–85.10.1023/A:1015319007880
44
BronsteinMDSalgadoLRde Castro MusolinoNR. Medical management of pituitary adenomas: the special case of management of the pregnant woman. Pituitary (2002) 5(2):99–107.10.1023/A:1022364514971
45
ColaoADi SarnoACappabiancaPDi SommaCPivonelloRLombardiG. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med (2003) 349(21):2023–33.10.1056/NEJMoa022657
46
AuriemmaRSPeroneYDi SarnoAGrassoLFGuerraEGasperiMet alResults of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation. J Clin Endocrinol Metab (2013) 98(1):372–9.10.1210/jc.2012-3039
Summary
Keywords
prolactin, pituitary tumor, dopamine agonist, pregnancy and outcome
Citation
Almalki MH, Alzahrani S, Alshahrani F, Alsherbeni S, Almoharib O, Aljohani N and Almagamsi A (2015) Managing Prolactinomas during Pregnancy. Front. Endocrinol. 6:85. doi: 10.3389/fendo.2015.00085
Received
07 March 2015
Accepted
10 May 2015
Published
26 May 2015
Volume
6 - 2015
Edited by
Corin Badiu, Carol Davila University of Medicine and Pharmacy, Romania
Reviewed by
Akira Shimatsu, National Hospital Organization Kyoto Medical Center, Japan; Hidenori Fukuoka, Kobe University Hospital, Japan; Jacqueline Trouillas, University Lyon 1, France
Copyright
© 2015 Almalki, Alzahrani, Alshahrani, Alsherbeni, Almoharib, Aljohani and Almagamsi.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Mussa Hussain Almalki, Obesity, Endocrine, and Metabolism Center, King Fahad Medical City, 7062, Ajman street, Riyadh 13314-3397, Saudi Arabia, m2malki@yahoo.com
Specialty section: This article was submitted to Pituitary Endocrinology, a section of the journal Frontiers in Endocrinology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.